Source comparison
BPC-157 Golfer's Elbow Mechanism: Protocol Comparison
Subcutaneous (local) Direct diffusion to medial epicondyle tendon; highest local concentration within 2–4 hours 250–500 VEGF upregulation detectable at 7–10 days; subjective pain reduction often reported at 10–14 days Best for localized tendon injury; requires
This comparison does not assign a generated winner or score.
- Subcutaneous (local)
- Direct diffusion to medial epicondyle tendon; highest local concentration within 2–4 hours
- 250–500
- VEGF upregulation detectable at 7–10 days; subjective pain reduction often reported at 10–14 days
- Best for localized tendon injury; requires precise injection technique to avoid nerve proximity
- Subcutaneous (systemic)
- Systemic circulation; reaches tendon via capillary perfusion; lower peak local concentration
- Similar timeline but may require higher cumulative dose for equivalent local effect
- Appropriate when multiple tendon sites involved or when local injection skill is unavailable
- Oral (capsule)
- First-pass hepatic metabolism reduces bioavailability by 60–80%; relies on gastrointestinal absorption
- 500–1000
- Unclear. Oral bioavailability for BPC-157 is poorly characterized in human studies
- Not recommended for targeted tendon repair; insufficient evidence for mechanism activation at therapeutic doses